Creators of Anti-Obesity Pill Test Effects on Heart Disease
Posted on: Thursday, 18 November 2004, 03:00 CST
Not content with having a drug that might merely fight obesity and smoking, the company developing the eagerly anticipated pill will soon launch studies to see whether it can treat and prevent clogged arteries and heart disease.
The reason the drug looks promising is that even the one-third of people who didn't lose weight on rimonabant, or Acomplia, still had improvements in cholesterol and other heart-disease risk factors, said Dr. Douglas Greene, the vice president for corporate and regulatory affairs for Sanofi-Aventis, the French company developing the drug.
He also gave the first details on its safety and side effects, including the one major concern to emerge so far: a doubled risk of depression.
"We're trying to get the information forward without hyping or frightening people," Dr. Greene said. But he said the company considers the drug one of those "once-in-a-decade" developments that offer a radically new way to treat a variety of diseases.
Acomplia has generated unusual excitement because it attacks obesity and possibly other addictive behavior in a novel way - by blocking a pleasure center in the brain. People on the drug eat less.
At a meeting of heart specialists last week, doctors reported that the drug helped obese people lose an average of 19 pounds and keep it off for two years, longer than any other diet drug has been able to do. A previous study showed it could help smokers kick the habit.
The company is aiming to seek FDA approval in April to sell Acomplia for dieters and smokers. But Dr. Greene said Sanofi also might seek labeling saying it can be used to prevent metabolic syndrome - a collection of problems including big waistlines, high cholesterol and high blood sugar that are known to put people at high risk of heart disease. If so, it would be the first drug marketed that way.
Studies involving 5,560 obese people found that those on the optimal dose of Acomplia had improvements in cholesterol, the type and amount of fat particles in their blood, and levels of key proteins involved in inflammation, which can cause artery blockages.
Source: Augusta Chronicle, The
Related Articles
- In Month of the Heart, Scientists Identify Better Way to Predict Heart-Disease Risk
- Researchers Identify New Drug Targets For Huntington's Disease
- OTC Drugs May Cut Parkinson's Disease Risk
- Drug Attacks HIV in a New Way
- Heart Failure Linked to Dementia Risk
- Statin Drug Potential for Alzheimer's Disease Bolstered By Recent Studies
- Greening disease spreads in Brazil orange crop
- Florida and Federal Officials Strive to Curb Citrus Greening Disease
- State, Federal Officials to Form Task Force on Citrus Greening Disease
- Drug Companies Research Rare Diseases in North Carolina
 |
 |
User Comments (0)
RSS Feeds